"Concomitant immunity" in murine tumours of non-detectable immunogenicity. by Ruggiero, R. A. et al.
Br. J. Cancer (1985), 51, 37-48
"Concomitant immunity" in murine tumours of
non-detectable immunogenicity
R.A. Ruggiero, O.D. Bustuoabad, R.D. Bonfil, R.P. Meiss & C.D. Pasqualini
Instituto de Investigaciones Hematol6gicas and Centro de Estudios Oncol6gicos, Academia Nacional de
Medicina, Las Heras 3092, 1425 Buenos Aires, Argentina.
Summary Various immunization assays were used to demonstrate the lack of immunogenicity of three
BALB/c tumours of spontaneous origin and of a fourth one resulting from foreign body tumorigenesis. All
four tumours inhibited the growth of a second implant of the same tumour into the contralateral flank. In
our tumour models "concomitant immunity" (1) was not mediated by macrophage or T-cell dependent
immune reactions: both thymectomized BALB/c and nude mice (treated or untreated with silica) gave the
same results as intact mice; (2) showed some degree of non-specificity, inhibiting the growth of a different
tumour in 3/4 cases; though, the existence of a specific component could not be discarded; (3) was
proportional to the volume of the primary tumour at the time of the second challenge; (4) was dependent on
actively growing primary tumour, not being obtained with progressively increasing daily inocula of irradiated
tumour cells; (5) was detectable in an actively growing secondary tumour: recurrent growth after partial
surgical excision was inhibited and (6) involved cytostasis of the secondary tumour: a syngeneic graft of the
overlying skin led to tumour growth while histological studies revealed the presence of viable tumour cells. It
is postulated that "concomitant immunity" or resistance can be generated without the active participation of
the immune system and that tumour-related factors are, in certain cases, responsible for blocking the growth
of secondary tumours.
In cancer research there is a phenomenon known as
"concomitant immunity" according to which a
tumour-bearing host resists a second implant of its
own tumour at a different site. It was first
described by Ehrlich (1906) and Bashford (1908)
devised the term. Since then, apart from a few
isolated papers (for reviews see Roffo, 1914;
Woglom, 1929; Vaage, 1971) this paradoxical
phenomenon remained forgotten for almost 60
years. Even now only few laboratories are
dedicated to the study of "concomitant immunity"
(for review, see Gorelick, 1983b) in spite of its
possible relevance to the mechanism of metastasis
control. In this regard, it has been repeatedly
observed that the removal of a murine
metastasizing tumour is followed by an abrupt
increase in metastatic growth (Crile & Deodhar,
1971; Gorelik, 1982). This would suggest that the
primary tumour exerted a controlling action on its
metastases which could be considered as a natural
"secondary implant". On the whole, "concomitant
immunity" has been evaluated during the growth of
tumours induced by carcinogenic agents which are
strongly immunogenic and in consequence an
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immunological interpretation has been favoured.
However, the demonstration of non-specificity in
some systems (Kearney & Nelson, 1973; North &
Kirstein, 1977) and the detection of "concomitant
immunity" with tumours of weak antigenicity
(Yuhas et al., 1975; Malenica & Milas, 1979) do
not fall in easily with this explanation. Further-
more, the phenomenon has also been observed in
association with human tumours (Southam &
Brunschwig, 1961; Southam, 1968) which can best
be compared with animal tumours of spontaneous
origin. In this paper, the detection of "concomitant
immunity" is reported with three mouse tumours of
spontaneous origin and with a fourth one induced
by foreign body tumorigenesis; the non-
immunogenic nature of these tumours is
demonstrated by various procedures and in
consequence the immunological interpretation of
the phenomenon is questioned.
Materials and methods
Animals
BALB/c, and Fl (BALB/cxDBA/2) mice of both
sexes and 2-4 months old were used throughout.
They were raised in our own colony and
maintained on Cargill pellets and water ad libitum.
Nude BALB/c mice were obtained from the
Comisi6n Nacional de Energia At6mica, Argentina,
and kept under relatively aseptic conditions.
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Animals were age and sex matched' within each
experiment.
Tumours
The following 4 tumours were used for "con-
comitant immunity" studies.
LB Lymphoid leukaemia which arose
spontaneously in a 6 month old BALB/c male. It
was maintained by s.c. serial passages in syngeneic
mice and was used between passages 40 and 87. It
grows to a large size in situ and at autopsy,
infiltration of lymph nodes, spleen and liver can be
seen. The number of s.c. injected viable tumour
cells required to give a 50% probability of lethality
(LD50) was 103. In order to determine whether
active viral replication was involved, one month old-
BALB/c mice (n=11) were inoculated i.p. with
acellular extracts of LB: they did not develop
leukaemia, during 15 months of observation.
CEI Undifferentiated epidermoid carcinoma
which arose spontaneously in a 12 month old
BALB/c female; it was maintained by syngeneic s.c.
serial passages and used between passages 2-6. It is
a slow growing tumour with LD50 of 11,250 cells
and at autopsy lung metastases are occasionally
encountered.
CM Mammary adenocarcinoma which arose
spontaneously in a 12 month old BALB/c female; it
was maintained by syngeneic s.c. serial passages
and used between passages 1-3. It is a slow
growing tumour with LD50 of 104 cells which does
not give rise to metastases.
PX Fibrosarcoma which was induced by a foreign
body (glass cylinder) 6 months after s.c. implan-
tation in a BALB/c female, as described previously
(Pasqualini et al., 1973). It was maintained by
syngeneic s.c. serial passages of which passages
106-135 were used. The tumour grows in situ and
does not give rise to metastases.
The following 4 tumours were used as controls in
different experiments:
P-388 Lymphoid leukaemia induced by methyl-
cholanthrene in 1957; subline Ps78R07 was recently
obtained from Arthur D. Little Co., Cambridge,
Mass. It was maintained by i.p. serial passages in
(BALB/c x DBA/2) Fl mice but used as a s.c.
transplant.
CS A mammary carcinoma originally induced by
MMTV (murine mammary tumour virus) kindly
supplied by Dr Diana Lopez, University of Miami.
The tumour was transplanted s.c. in BALB/c mice.
It is slow growing with LD50 of 3.2 x 104 cells and
does not metastasize.
MC-C Fibrosarcoma which arose in a 5 month
old BALB/c male 3 months after the implantation
of a methylcholanthrene pellet. It was maintained
as a syngeneic serial line of which passages 3-5
were used. It is a slow growing tumour with a
regression rate of 13% and LD50 of 5 x 104 cells.
MC-D Fibrosarcoma induced by methylcholan-
threne in a 6 month old BALB/c male which
appeared 4 months after the implantation of a
methylcholanthrene pellet; it has a regression rate
of 44% and LD50 of 106 cells. It was used as s.e.
transplant between passages 3-5.
Thymectomy in newborn mice
Within 24h after birth BALB/c mice were
anaesthetized on ice and their thymus was removed
by vacuum aspiration. Thymectomy was controlled
at autopsy by macro and microscopic observations.
Histological observations showed reductions in
number and size of lymph node follicles with
atrophy of the paracortical zone (thymus-
dependent).
Experimental modelfor "concomitant immunity"
The primary tumour was implanted s.c. in the right
flank of mice followed at different intervals by a
second s.c. implantation in the contralateral flank
of either the same tumour or a different one;
suppression or delay of growth of the second
tumour implant was considered as a measure of
"concomitant immunity". Tumour volume was
expressed according to the formula of Attia &
Weiss (1966): volume=0.4 (ab2) where a and b
represent the larger and smaller diameters
respectively. Excellent reproducibility was found
from one experiment to another and therefore data
from several experiments were pooled.
Immunization assays
The following procedures were carried out:
Irradiated cells Cell suspensions were irradiated
with 90Gy in a plastic irradiation chamber; X-rays
were generated in a Philips 250/15 Radiotherapy
apparatus at 220kv, 14mA and filtered with 1 mm
Al. The dose rate was 3.51 Gymin 1 at a focus-
target distance of 29cm. In most cases the animals
were pretreated with 2 s.c. doses of 4 x 106
irradiated tumour cells, 15-22 and 7-12 days before
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cyclophosphamide (Endoxan, Labinca S.A.
Argentina) was inoculated i.p. 2 days before
pretreatment. In another experiment, only one dose
of 2 x 106 irradiated cells in complete Freund's
adjuvant was inoculated, 15 days before tumour
challenge.
Mitomycin C-treated cells Tumour cell
suspensions (107ml-1) were incubated at 370C for
45min with 50 gmnl' Of Mitomycin C (Sigma
Chemical Co., St Louis, USA) and washed 3 times
with saline solution. The animals were pretreated
s.c. with 106 of these cells 15 days before tumour
challenge.
Glutaraldehyde-treated cells Tumour fragments
were fixed in 3% glutaraldehyde (Sigma Chemical
Co., St Louis, USA) in PBS at 37°C for 45min,
washed 3 times at 4°C, and implanted s.c. 14 and 8
days before tumour challenge.
Heat-treated cells Tumour cells (106-107) heated
at 80-90°C for 1 min were inoculated s.c. 19 and 7
days before tumour challenge.
Cold-treated cells Tumour cells (2 x 106) which
had been maintained at -15°C for 45min were
inoculated s.c. 21 and 7 days before tumour
challenge.
Sublethal doses Mice which had survived a first
tumour implant were re-inoculated with various
doses of cell suspensions of the same tumour.
Tumour implantation and excision S.c. tumour
implants were surgically excised when their volume
had reached 400-600mm3; 2-3 weeks later, a
second tumour implant was carried out in the
contralateral flank in the mice which had not
relapsed.
Tumour neutralization test
The anti-tumour activity of lymph node or spleen
cells of tumour-bearing mice was investigated with
the in vivo Winn test (Winn, 1961), by mixing them
with tumour target cells at various lymphocyte-
target cell ratios. The cells were inoculated by the
s.c. route and tumour growth evaluated.
Statistical analysis
x2 and Student's t-test were used. Differences were
considered significant when the P value was <0.05.
Results
Detection of "concomitant immunity"
"Concomitant immunity" against LB: BALB/c mice
were inoculated s.c. with 106 LB cells (average
latency to death, 22 days) in the right flank; they
received a second s.c. implant of either 106, 105 or
104 LB cells in the left flank 0, 3, 6, 9 and 11 days
later when the primary tumour volumes were 0, 0,
150, 400 and 800mm3, respectively. The controls
received only the left flank inoculum. As can be
seen from Table I, "concomitant immunity" was
proportional to the tumour growth of the primary
implant. Thus, mice with a primary tumour implant
of 106 cells resisted a simultaneous secondary
implant of 104 LB cells but not of higher doses.
Similarly, a second implant of 105 LB cells carried
out on day 6 did not grow while one of 106 led
only to a slight decrease in second tumour takes.
Finally, all the animals challenged with a second
implant of 106 cells on day 9 or 11, were able to
resist it. In two other experiments, using primary
implants of 105 and 104 LB cells, (average latency
of 24 and 30 days respectively) similar results were
obtained, except that "concomitant immunity" was
detected later. In all cases the observation period
between the inoculum in the left flank and the
death of the animals was 11-22 days.
"Concomitant immunity" against CEI: A total of
20 BALB/c mice were inoculated s.c. with 5 x 105
CEI cells in the right flank (average latency, 50
days); when the tumour size reached 40mm3 (n=6),
300mm3 (n =9) or 1800mm3 (n =5), a second
implant of 5 x 105 CEI cells was carried out in the
left flank. A control group of 18 mice received only
the tumour cells in the left flank. As can be seen in
Figure 1, no "concomitant immunity" was detected
in animals bearing the smallest primary tumour but
was evident in the other two groups bearing larger
primary tumours in which only 3/9 and 3/5,
respectively, showed tumour growth at the end of
the experiment.
"Concomitant immunity" against CM: Seven
BALB/c mice received a primary s.c. implant of
2 x 106 CM cells in the right flank (average latency,
50 days); when tumour size reached 600mm3 (n=4)
or 2000mm3 (n=3), a second s.c. implant of
1.5 x 106 CM cells was carried out in the
contralateral flank. The controls (n= 13) received
only the second tumour challenge. As shown in
Figure 2, in the presence of the larger primary
tumour, the second implant did not grow at all
while in the other group the secondary implant
showed significantly retarded growth. The
observation period between the inoculum in the left
flank and the death of the animals was 25-33 days.
"Concomitant immunity" against Px: A total of 46
BALB/c mice were implanted s.c. with a solid40 R.A. RUGGIERO et al.
Table I Inhibition of tumour growth at the site of the second tumour
-implant as a measure of"concomitant immunity" generated by a lymphoid
leukaemia (LB) in normal, thymectomized and nude BALB/c mice
Tumour inocula Exp.a Control Exp. Control Exp. Control
1st (right flank)
No. of LB cells (day 0)
2nd (left flank)
No. LB cells (on day)
Normal mice
xTmiceb
nude mice
(0)
(3)
(6)
(9)
(11)
(6)
(9)
(7)
(11)
106 106 106
106 106 105 105 104 104
Tumour takes in leftflank/No. ofmice
12/12
7/7
14/18
0/6C
0/6c
6/6
3/3
12/12
4/4
6/6
0/6C 6/6
1/6C 6/6
6/6 6/6
5/5 4/4
0/36d 18/18
1/12 12/12
0/6C 6/6
1/1od 7/7
aExperimental group received both LB tumour inocula while the
control group received only the second inoculum.
bBALB/c mice thymectomized at birth.
cP<0.01 as calculated by X .
dP <0.001 .
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Figure 1 Resistance of BALB/c tumour-bearing mice
to a second challenge of the same tumour (5 x 105 CEI
cells) carried out when the first implant had reached a
volume of 40mm3 (0 O), 300mm3 (A A) or
1800mm3 (A A); controls (0 0) received
only the second tumour challenge. The secondary
tumour grew in (0 O) as in the controls, while it
was significantly decreased (t-test) in both incidence
and volume (mm3+s.e.) in the other groups.
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Figure 2 Resistance of BALB/c tumour-bearing mice
to a second challenge of the same tumour
(1.5 x 106CM cells) carried out when the first implant
had reached a volume of 600mm3 (0 O) or
2000mm3 (A A); controls received only the second
tumour challenge (0 0). Secondaiy tumour
growth (mm3+s.e.) was significantly decreased (t-test)
as compared with the controls, in direct relation with
primary tumour volume.
/....
l
.1 -- -
r
_-
_-
_
4 4
_"CONCOMITANT IMMUNITY" IN MURINE TUMOURS
E
E
0
E
E
E
0
E I-
Time (d) after 2nd inoculum
Figure 3 Resistance of BALB/c tumour-bearing mice
to a second challenge of the same tumour (1 mm3 Px
fragment) carried out when the first implant had
reached a volume of 600mm3 (0 O), 1400mm3
(A\ A),2700mm3(A A)or5400mm3(L0 O);
controls (0 0) received only the second tumour
challenge. Secondary tumour growth (mm3 + s.e.) was
significantly decreased (t-test) in direct relation with
primary tumour volume except in the case of the
largest primary tumour which did not lead to
"4concomitant immunity" (EOI OE).
fragment (1 mm3) of Px by trocar, in the right flank
(average latency, 30 days) and when tumour size
reached 600mm3 (n= 12), 1400mm3 (n= 12),
2700mm3 (n=12) or 5400mm3 (n=10), a
secondary s.c. implant of Px was carried out in the
contralateral flank. The controls (n =28) received
only the second tumour challenge. As can be seen
in Figure 3, the growth of the second implant was
significantly inhibited in direct proportion to the
size of the primary tumours except in the presence
of a very large one, in which case, the second
implant reached a volume similar to that of the
controls.
It is important to point out that in the four
models studied the primary tumour grew and killed
the host independently of the fate of the second
inoculum.
Nonspecificity of "concomitant immunity"
Animals bearing a primary tumour were challenged
with a second implant of a different tumour, to test
the specificity of "concomitant immunity".
In a first experiment (LB-P388) sixteen
(BALB/c x DBA/2) Fl mice were inoculated, on day
0, with 106 LB cells in the right flank and were
Time (d) after 2nd inoculum
Figure 4 Non-specific resistance of (BALB/c x
DBA/2) Fl mice bearing LB tumour to a second
challenge of P-388 tumour cells. Experimental groups:
Fl mice were inoculated on day 0 with 106 LB tumour
cells in the right flank; then they received in the
contralateral flank 105 P-388 tumour cells on day 7
(A iA) or 106 P-388 tumour cells on day 9
(0 0). Control groups: Received only 105 (A A) or 106 ( 0) P-388 tumour cells in
the left flank. A significant decrease (t-test) in P-388
tumour growth (expressed as mm3 + s.e.) was obtained
in mice bearing LB tumour as compared with
the corresponding controls.
divided into 2 groups, 10 mice receiving on day 7,
105 P-388 cells in the left flank and 6 mice receiving
on day 9, 106 P-388 cells. The 16 control mice
received only the corresponding inoculation in thbe left flank, that is, only 105 or 106 P-388 cells. As
shown in Figure 4, a marked and significant decrease in the growth of the second implant was
observed in both experimental groups, as
compared with the controls.
In a second experiment (CS-LB) six BALB/c mice
were inoculated s.c., on day 0, with 106 CS cells
(slow growing tumour); 15 days later, when this
tumour was not yet palpable, a second s.c. implant of 100 LB cells (fast growing tumour) was carried
out in the contralateral flank. In this case
"concomitant immunity" was evident against CS
which, on day 35, did not grow in 3 animals while
in the remaining 3 it grew less well (600mm3) than
in the 6 controls (970mm3) bearing only CS. The
phenomenon observed was due to the rapid growth of the second tumour implant (LB) which caused
"concomitant immunity" against the primary
tumour (CS). The observation period was limited to
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35 days since by that time the animals began to die
of LB tumour.
In a third experiment (CS-LB) four BALB/c mice
received 106 CS cells in the right flank and 49 days
later, when the tumour measured 6000mm3, 106 LB
cells were inoculated s.c. in the contralateral flank.
Within 2 weeks the 4 mice had died of the CS
tumour, during which time the LB implant had not
grown at all in 2 mice while in the remaining 2 it
had grown much less (300mm3) than in the
corresponding 6 controls (1600mm3).
In a fourth experiment (LB-Px) twelve BALB/c
mice were s.c. implanted with 106 LB cells; then the
animals received 6 or 9 days later a solid fragment
(1 mm3) of Px cells in the contralateral flank. No
difference in tumour growth of the second implant
was observed as compared with mice bearing only a
Px implant i.e., no "concomitant immunity" was
detected in this case.
"Concomitant immunity" in athymic mice
The participation of T lymphocytes in the
development of "concomitant immunity" was
studied in both nude mice and in mice
thymectomized within 24h after birth. Results are
summarized in Table I.
A total of 12 BALB/c mice thymectomized at
birth were inoculated s.c. with 106 LB cells when
they were 2-3 months old; on day 6, when the
tumour measured 200mm3, 6 mice received a
second implant of 105 LB cells in the contralateral
flank, while the remaining 6 animals received 106
LB cells s.c. on day 9, when the primary tumour
had reached 1000mm3. As can be seen in Table I,
"concomitant immunity" was observed in both
groups as compared to controls bearing only the
second implant and did not differ from that
registered in euthymic mice. In another experiment,
16 BALB/c nude mice were inoculated s.c. with 106
LB cells and on day 7, when the tumour measured
120mm3, 10 of them received s.c. 105 LB cells in
the contralateral flank, while the remaining 6
received s.c. on day 11, a second implant of 106 LB
cells. As shown in Table I, "concomitant
immunity" was evident in both groups as compared
with controls bearing only the second implant and
did not differ from that registered in euthymic
mice. It is interesting to note that in nude mice LB
cells grew more slowly than in normal mice;
therefore the second implant was carried out 1 and
2 days later.
"Concomitant immunity" in silica treated mice
Since silica treatment is considered to depress the
functions of macrophages (Allison et al., 1966;
Gorelick, 1983a) and presumably of NK cells (Djeu
et al., 1979; Gorelik, 1983a), in order to elucidate
their participation in the development of
"concomitant immunity", 6 nude and 6 euthymic
BALB/c mice received a s.c. implant of 106 LB cells
in the right flank and 7 days later were inoculated
i.v. with 2mg of silica (1 gm particles, Sigma
Chemical Co., St Louis, USA) and 1 h later they
were challenged s.c. with 105 LB cells in the left
flank. The development of "concomitant
immunity" was not altered by this treatment, i.e.
there was no secondary tumour growth. The same
results were obtained in 3 BALB/c mice which
received 1 mg of silica s.c. at the same site and
simultaneously with the secondary tumour implant
i.e. 'concomitant immunity" was again evident.
The effect of i.v. silica (2mg) on NK cells and
macrophages was evaluated in preliminary
experiments.
Effect on NK cells Splenocytes of 2 BALB/c mice
treated 3 days before with i.v. silica showed a 14%
decrease in cytolysis (using a 4h 51Cr release assay)
of YAC-1 cells (a tissue culture cell line of YAC, a
Moloney virus-induced lymphoma of A/J origin), as
compared with splenocytes of 2 normal BALB/c
mice.
Effect on macrophages The phagocytic activity (K)
of the reticuloendothelial system was studied by
measuring the capacity of test animals to clear i.v.
injected colloidal carbon from their peripheral
blood and was determined by the formula:
K=log1o 1D3min-log10 D15 min
12min
where OD3 min and OD15 min represent the optic
densities of the blood, 3 and 15min after the
carbon injection (Biozzi et al., 1953; Levy &
Wheelock, 1975). Phagocytic activity of 6 BALB/c
mice treated 1 day before with i.v. silica was
significantly depressed (K=0.038+0.008) as
compared with that of 5 normal mice
(0.080+0.005; P<0.01).
Undetectable immunogenicity ofthefour tumours
generating "concomitant immunity"
Immunization assays: LB As can be seen in Table
II, different procedures were carried out. In all
cases, 12-30 putatively immunized BALB/c mice
together with the corresponding normal controls
were challenged s.c. with 106, 105, 104, 103 or 102
LB cells and the LD50 value was calculated. In
general, the immunization procedures were not
capable of increasing LD50 or altering tumour
growth. A slight increase in LD50 was registered in"CONCOMITANT IMMUNITY" IN MURINE TUMOURS 43
Table II Lack of immunogenicity of a lymphoid
leukaemia (LB) expressed as LD50 in syngeneic BALB/c
mice pretreated with different immunization procedures,
using two methylcholanthrene-induced tumours (MC-C
and MC-D) as immunogenic controls
LD50
Immunization assays LB MC-C MC-D
Control
(without pretreatment) 103 5 x 104 106
1 Implantation-excision a >4 x 106 >5 x 106
2 Sublethal tumour doses 103 >5 x 106
3 X-irradiated cells
+complete Freund
adj. 5.6 x 103
4 X-irradiated cells
+cyclophosphamide 1.3 x 103
5 X-irradiated cells 7.7 x 102 >5 x 106
6 Mitomycin C treated
cells 7 x 102
7 Cold-inactivated cells 5.6 x 103
8 Heat-inactivated cells <3 x 103
(% spontaneous
regression) 0 13 44
aThe mice died of leukaemic dissemination except for 2
which did not resist a subsequent tumour challenge.
mice treated with irradiated cells in complete
Freund's adjuvant or with cold-inactivated cells,
however, when these presumably immunized mice
were re-challenged with graded doses of LB cells,
no difference in LD50 was observed compared with
the controls. Furthermore, when LB cells fixed in
glutaraldehyde were used to immunize 12 BALB/c
mice a subsequent s.c. tumour challenge with 106
LB cells grew at the same rate as in the controls;
this group could not be included in Table II
because only 1 dose was used as challenge so that
LD50 could not be calculated. Another procedure
used to test tumour immunogenicity was that of
tumour implantation followed by surgical
extirpation. However, out of a total of 78 mice
bearing a 6-12 day LB growth resulting from the
s.c. inoculation of 105 or 106 cells, only 2 survived
and proved to be non-immunized since a
subsequent challenge with 104 LB cells grew as in
the controls. The remaining mice died of leukaemic
dissemination in spleen, lymph nodes and liver and
a few of them showed local relapse at the
extirpation site. As can be seen in Table II, the lack
of immunogenicity of LB is in sharp contrast with
the results obtained with 2 methylcholanthrene-
induced fibrosarcomas (MC-C and MC-D). The
spontaneous regression rate of these methylcholan-
threne tumours is a further index of their strong
immunogenicity contrasting with the fact that mice
bearing LB never showed tumour regression in
more than 500 animals used in these experiments.
CEI The only immunization procedure carried out
was that of tumour implantation and excision. The
results indicate that in tumour-excised mice, LD50
(3200 cells) was even lower than that observed in
the controls (11,250 cells). Out of a total of 30
mice operated upon, 15 relapsed locally. Sponta-
neous tumour regression was never seen (100 mice).
CM Of 16 mice bearing a CM tumour which were
operated upon, the 12 animals which did not show
local recurrence were challenged s.c. with graded
doses of CM cells. Both the pretreated and control
mice showed the same LD50 of 104 cells and
similar latency to death, ranging from 50 to 65 days
-depending on the doses used. No spontaneous
tumour regression was ever seen (100 mice).
Px Two immunization assays, pretreatment with
sublethal tumour doses and implantation-excision
were carried out in 52 BALB/c mice. Challenge
doses consisted of fragments of Px of different size
and the results obtained did not reveal any degree
of resistance (measured as tumour takes or growth
rate) in pretreated or operated mice as compared
with the controls. LD50 was not calculated because
of the difficulty of counting viable fibrosarcoma Px
cells in a reproducible way. Local recurrence in
excised-tumour mice was 50%. No spontaneous
tumour regression was ever seen (300 mice).
Winn test Spleen or lymph node cells were
obtained from BALB/c mice bearing either one or
two LB implants, (of which the second implant
failed to grow because of "concomitant immunity")
and mixed with 5 x 103 LB cells in different
proportions. The cell mixture was then inoculated
s.c. into syngeneic mice. As shown in Table III, no
significant difference (X2 test) could be observed in
the experimental groups compared with controls
receiving only LB cells mixed with normal spleen or
lymph node cells.
Miscellaneous observations concerning the
mechanism responsiblefor "concomitant immunity"
Taking into account that the development of
"concomitant immunity" was proportional to the
tumour volume of the first implant, the possibility
was considered that the repeated inoculation of
irradiated LB cells in progressively larger daily
doses, always at the same s.c. site, might mimic
tumour load and thereby generate "concomitant44 R.A. RUGGIERO et al.
Table III Winn test: Tumour incidence after inoculation of different
lymphocyte: LB-tumour-cell ratios in BALB/c mice.
Ratio Tumours
Lymphocytesfrom lymphocytes:LB cells n/total %
0:1 (5 x 103) 15/30 50
Normal spleen 50:1 8/12 66
100:1 5/12 42
10:1 2/6 33
Normal lymph node 50:1 11/18 61
100:1 6/12 50
Spleen of LB-bearing mice 50:1 6/6 100
(1 implant') 100:1 2/6 33
Spleen of LB-bearing mice 50:1 10/12 83
(2 implantsb) 100:1 5/6 83
Right inguinal lymph node of 50:1 2/6 33
LB-bearing mice (1 implant') 100:1 6/6 100
Right inguinal lymph node of 50:1 6/6 100
LB-bearing mice (2 implantsb) 100:1 6/6 100
Left inguinal lymph node of 75:1 6/6 100
LB-bearing mice (1 implanta)
Left inguinal lymph node of 10:1 1/6 16
LB-bearing mice (2 implantsb) 50:1 8/12 66
100:1 6/12 50
Left inguinal lymph node of 50:1 6/6 100
LB-bearing nude mice (2 implantsb) 75:1 6/6 100
aThe first implant was always carried out s.c. in the right flank.
bThe second implant of LB cells in the left flank was not growing due to
"concomitant immunity."
immunity". Therefore, 7 BALB/c mice were
inoculated s.c. into the right flank with 9 daily
doses imitating the increase in volume of a tumour
originated from an inoculum of 106 LB cells; on
day 6, the animals were challenged s.c. with 105
viable LB cells in the left flank. No decrease, rather
a slight increase in tumour size, was observed
compared with control mice bearing only the
tumour implant in the left flank; i.e. no
"concomitant immunity" had been generated.
In order to determine whether "concomitant
immunity" could inhibit not only secondary
implants but also actively growing tumour cells, 18
BALB/c mice were inoculated s.c. with 106 LB cells
in both flanks. On day 6, the incipient LB tumour
growing in the left flank of 12 mice was partially
excised, leaving behind a mass of 2 x I05 or 104 LB
cells, while in the remaining 6 mice, the tumour was
excised on day 9, leaving behind a cluster of
-2x 103 LB cells. The number of LB cells left
behind was calculated indirectly in 12 mice which
were similarly operated upon and sacrificed to
count the remaining tumour cells. The fate of the
LB cells left at the operation site in the presence of
the growing tumour in the opposite flank was
compared with that ofcontrols operated upon in the
same way, but not bearing an LB tumour in the
right flank. The results showed that 2 x 105 LB
remaining cells grew independently of the presence
of the tumour in the contralateral flank, while 104
cells grew but at a slightly lower rate than in the
corresponding controls. However, when the number
of remaining LB cells was around 2 x 103 and the
size of the tumour at the contralateral flank was
larger, only 1/6 animals showed tumour growth,
while in 5/6 controls the tumour grew; the
observation period between the operation and the
death of the animals was 8-14 days and it is
interesting to note that 2 x 105, 104 or 2 x 103 LB
growing cells left behind after excision gave rise to
a palpable tumour in only 2, 3 and 4 days
respectively. This is a very short tumour latency
compared with that required for s.c. inocula of
2x 105, 104 or 2 x 103 LB cells: 7, 14 and 18 days,
respectively.
In order to determine whether viable tumour cells
were present in the lymph nodes draining a second
LB implant, which was not growing because of
"concomitant immunity", the following experiment
was carried out. Two BALB/c nude mice bearing a
growing LB tumour in the right flank and a second
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axillary and the left inguinal lymph nodes were
excised. These 4 nodes were implanted s.c. by
trocar in the left flank of 4 BALB/c mice, 2 of
which had received in the right flank a s.c. LB
implant of 106 cells, 7 days before. The results
indicate that as a first implant, these lymph node
cells led to tumour growth, but as a second implant
they did not grow, demonstrating that the lymph
nodes draining non-growing secondary implants
contained viable tumour cells which could be
inhibited by "concomitant immunity".
Such a cytostatic mechanism was confirmed by a
syngeneic skin graft. Donor skin from 8 BALB/c
mice came from the site of a second LB implant
which had been carried out 7 or 11 days before and
which was not growing. In all of 8 grafted mice a
tumour developed at the site of the graft and grew
progressively, leading to the death of the animals.
This would indicate that "concomitant immunity"
was capable of blocking tumour growth by sa
reversible cytostatic mechanism. As preliminary
results, a further confirmation of the cytostatic
state of the tumour cells undergoing "concomitant
immunity" was obtained from histological studies.
(Figure 5).
Discussion
"Concomitant immunity" was demonstrated in
association with the four tumours studied; three of
these arose spontaneously in our mouse colony and
the fourth resulted from the implantation of a
foreign body; all of them proved to be non-
immunogenic by several immunological procedures.
The intensity of "concomitant immunity" was
proportional to the tumour volume of the first
implant. However, with foreign body tumorigenesis
the phenomenon tended to disappear when the first
implant had reached a critical size; such a large
volume was never attained with the other three
tumours which may explain why a terminal
decrease in "concomitant immunity" was not seen,
although particular differences among tumours in
the generation of this phenomenon cannot be
discarded.
Three different theories have been proposed to
explain "concomitant immunity". Historically, the
theory of atrepsis was the first one put forward by
Ehrlich (1906). It postulates that nutrients essential
for tumour growth are consumed by the primary
tumour making it difficult for a second implant to
develop. In our experiments, the fact that when a
secondary implant of 105 LB cells did not grow,
one of 106 could grow, does not seem to favour this
explanation since the lack of nutrients should have
inhibited both inocula, unless the larger one was
able to attract more of the necessary potential
growth factors. Furthermore, when fibrosarcoma
Px had acquired a very large size and presumably
should have been consuming more nutrients
according to this theory, "concomitant immunity"
was decreased.
The second theory was originally proposed by
Bashford (1908) and states that as a tumour grows
it generates an immunological response which even
though it is not strong enough to inhibit primary
tumour growth, is still capable of preventing the
development of a relatively smaller second implant.
In the last 15 years, this immunological explanation
has had many advocates (Deckers et al., 1973;
Vaage, 1971; North et al., 1982) but their
experiments involved immunogenic tumours induced
either by carcinogenic agents or by oncogenic
viruses. Such an immunological mediation does not
provide a satisfactory explanation for our
experiments. Firstly, it has not been possible to
demonstrate any degree of immunogenicity in the
tumours studied. A similar lack of immunogenicity
of tumours of spontaneous origin has been
demonstrated by Hewitt et al. (1976) in 27 mouse
tumours and by Middle & Embleton (1981) in 32
rat tumours. In the second place, nude mice or
those thymectomized at birth showed the same
development of "concomitant immunity" as the
normal controls, which would presumably discount
a main role for T-lymphocyte mechanisms.
Moreover, the i.v. treatment of athymic and normal
mice with silica did not alter the development of
"concomitant immunity" which would not favour
an active participation of macrophages. As for NK
cells, in spite of a reduction in cytolysis of YAC-1
cells (14%) in i.v. silica treated mice, the small
number of animals tested does not make it possible
to discount their participation in the development
of "concomitant immunity": further experiments
are being carried out. Gorelik (1983a) working with
long-passaged tumours also observed "concomitant
immunity" in nude and in normal mice treated i.p.
with silica.
The third theory was recently formulated by
Gorelik et al. (1981) who suggested that tumour
cells of the first graft produce or induce inhibitory
factor(s) which suppress the replication of tumour
cells of the second inoculum. This inhibitory
factor(s) is held to be non-tumour specific and to
function independently of the components of the
immune system. The production of such a factor(s)
would explain the suppressive effect which the local
tumour exerts on its metastases as well as their
accelerated growth following removal of the
primary tumour mass. This theory could also
explain the development of "concomitant
immunity" in immunodeficient mice as well as its
induction by non-immunogenic tumours. However,
such antimitotic factors capable of inhibiting a46 R.A. RUGGIERO et al.
Figure 5 Experimental group (a and b): Six days after a first s.c. implant of 106 LB cells in the right flank, 12
BALB/c mice received a second s.c. implant of 105 LB cells in the left flank which did not grow because of
"concomitant immunity". Skin from this site was removed 7 days later and histologically analyzed. Note that,
at the s.c. site of the second tumour implantation, there are non-infiltrating neoplastic LB cells (5a, H & E
x lOOorig.mag.) which are morphologically well preserved with no signs of necrosis (5b, H & E
x 250orig. mag.). Control group (c): 12 BALB/c mice received only 105 cells in the left flank; skin from this
site was removed 7 days later and histologically analyzed. Note the presence of abundant neoplastic LB cells
infiltrating the muscular layer and the dermis (5c, H & E x 100orig. mag.). This tumour was macroscopically
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second implant should presumably also affect the
growth of the primary tumour since the same cells
are involved. In our experiments, LB and Px
tumours have gone through several passages
without showing a decrease in their capacity to
generate "concomitant immunity". It is not easy to
visualize, in the context of this theory, why clones
of tumour cells sensitive to this antimitotic factor(s)
would be retained throughout the different passages
escaping an elimination by natural selection.
It is possible that "concomitant immunity" could
have two different causes: one immunological,
detected only with immunogenic tumours and a
second one, non-immunological, common to both
immunogenic and non-immunogenic tumours: in
the latter case, concomitant resistance would be a
better denomination. The fact that North &
Kirstein (1977) observed that in T-cell deprived
mice, "concomitant immunity" generated by
immunogenic tumours substantially decreased but
did not disappear would favour such an
interpretation.
An analysis of the three theories proposed to
explain "concomitant immunity" reveals that the
mechanisms implicated in its generation are not yet
well understood; the data presented herein indicate
that "concomitant immunity" or resistance
generated by spontaneous non-immunogenic murine
tumours would have the following characteristics:
(1) It does not seem to be mediated by macrophage
or T-cell dependent immune reaction; (2) It has
some degree of non specificity: a significant growth
inhibition of the secondary implant was obtained in
3/4 different tumour combinations; however, the
fact that "concomitant immunity" observed in LB
tumour-bearing mice against a second implant of
LB was stronger than that observed against P-388
or CS indicates that a specific component (not
necessarily immunological in our tumour models)
cannot be discarded; (3) It would operate by a
cytostatic mechanism: the second tumour implant
remains viable as demonstrated by in vivo
transplants and by histological studies. Using long-
passaged tumours, Gorelik (1983a) arrived at
similar conclusions. However, the questions we are
now trying to address are how long do the
cytostatic tumour cells of the secondary implant
remain in this dormant state and whether they will
eventually die; (4) Its induction is dependent on a
growing tumour mass: it could not be generated
with a serial and progressively higher inoculum of
irradiated LB tumour cells mimicking the increasing
tumour mass; (5) It affects not only secondary
tumour grafts but also actively growing tumour
cells: recurrent tumour growth after partial surgical
excision could be inhibited by "concomitant
immunity".
As a final consideration it must be noted that the
detection of "concomitant immunity" presents
several methodological difficulties. In effect, the
long latency period of relatively small secondary
implants may signify that the animals can die of the
primary tumour before the secondary one has had
a change to appear. On the other hand, a very large
secondary implant can overcome "concomitant
immunity" precluding its observation. Middle &
Embleton (1981) working with 5 spontaneous rat
tumours of non-detectable immunogenicity
observed that only one of them led to
"concomitant immunity"; however, with the other
four tumours the second implant was carried out
when the first one was either slightly or not
palpable at all. When we did experiments in the
same conditions "concomitant immunity" was not
detected; a larger primary tumour, or else a
proportionally smaller second inoculum was
needed.
It can be argued that the non-proliferation of the
secondary tumour due to "concomitant immunity"
is comparable to dormant metastases. On the other
hand, animal tumours of spontaneous origin have
been considered as the most appropriate model for
human cancer (Hewitt, 1978). Therefore,
experiments designed to explain the mechanisms
involved in "concomitant immunity" with these
tumours may eventually be of benefit for the
control ofhuman metastases.
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